Equities

Aethlon Medical Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Aethlon Medical Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)1.77
  • Today's Change-0.10 / -5.35%
  • Shares traded21.63k
  • 1 Year change-95.08%
  • Beta1.6488
Data delayed at least 15 minutes, as of Mar 03 2026 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Aethlon Medical, Inc. is a clinical-stage medical device company. The Company is focused on advancing the Hemopurifier (HP), a clinical-stage immunotherapeutic device intended for applications in cancer, life-threatening viral infections, and organ transplantation and other areas of significant unmet needs. In pre-clinical studies, the Hemopurifier has exhibited the capacity to remove harmful extracellular vesicles (EVs) and enveloped viruses from biological fluids, utilizing its proprietary lectin-based mechanism. These extracellular vesicles have been implicated in disease processes such as immune suppression and metastasis in cancer as well as in the progression of severe life-threatening infectious diseases. The United States Food and Drug Administration (FDA) has designated the Hemopurifier as a Breakthrough Device for the treatment of individuals with advanced or metastatic cancer who are unresponsive to or intolerant of standard of care therapy.

  • Revenue in USD (TTM)0.00
  • Net income in USD-11.52m
  • Incorporated1991
  • Employees9.00
  • Location
    Aethlon Medical Inc11555 Sorrento Valley Road, Suite 203SAN DIEGO 92121United StatesUSA
  • Phone+1 (619) 941-0360
  • Fax+1 (619) 941-0361
  • Websitehttps://www.aethlonmedical.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Profusa Inc0.00-39.09m1.33m0.00---------278.73-278.730.00-61.050.00-------599.88-----------------14.56---------849.77------
Leafbuyer Technologies Inc5.08m49.72k1.40m12.0028.57----0.27570.00050.00050.0508-0.0155.27--74.98423,414.205.16-44.28----44.4937.830.9786-21.61--1.05----15.5420.68136.74-27.51----
Escalon Medical Corp12.31m-279.31k1.82m39.00--1.61--0.1476-0.0464-0.04641.350.23912.604.266.40315,666.90-5.291.53-10.773.4843.8743.87-2.030.70261.06-11.330.1195--0.53955.09115.88---42.12--
Agape ATP Corp1.48m-2.71m1.89m16.00--0.0828--1.27-14.97-14.972.6122.830.104713.9960.1492,806.88-19.46-34.76-21.27-44.4452.6869.19-185.74-92.8616.18--0.0056---7.57---17.53------
Tivic Health Systems Inc482.00k-7.51m2.05m7.00--0.2409--4.24-9.87-9.870.59143.360.10022.0734.4368,857.14-156.00-118.40-178.18-148.80-58.095.50-1,557.26-610.995.86--0.00---33.6713.1831.40------
Work Medical Technology Group Ltd9.85m-1.07m2.05m238.00--0.0056--0.2083-240.65-240.653,397.15214.44------41,393.78--1.52--4.5623.8322.30-12.162.521.50-7.750.23190.00-14.41-28.4569.28---39.54--
ENvue Medical Inc2.69m-5.21m2.15m15.00--0.0471--0.8025-83.93-83.937.4642.000.09090.83646.45179,000.00-25.01-97.63-32.90-149.1830.0253.04-275.12-397.830.6675--0.0669--12.0537.000.1617------
Zynex Inc108.20m-73.96m2.16m1.00k------0.0199-2.43-2.433.49-1.341.262.207.64108,202.00-86.3110.48-203.5512.4271.9079.57-68.357.510.3174-12.223.19--4.3633.44-69.24-20.6129.29--
Aethlon Medical Inc0.00-11.52m2.46m9.00--0.2711-----49.09-49.090.006.900.00----0.00-158.03-86.44-199.49-98.06-------3,662.04----0.00-------9.67------
Encision Inc6.30m-380.94k2.53m22.00--1.36--0.4019-0.0284-0.02840.50570.11051.662.277.98286,353.60-10.05-3.17-14.19-4.4052.6451.47-6.05-2.010.9127-5.690.1094---0.464-3.0968.17--8.09--
Catheter Precision Inc730.00k-22.19m2.64m22.00--0.3837--3.61-37.38-37.380.93714.120.0281.646.3533,181.82-66.93-128.03-78.29-160.1292.60-242.70-2,393.84-15,268.880.4569-66.840.0449---4.98-19.8969.45---24.21--
Nuwellis Inc8.17m-16.56m2.79m38.00--0.5204--0.3418-107.66-107.6626.642.871.111.656.71214,947.40-225.22-87.78-390.32-108.5359.0757.73-202.83-195.831.42-1.050.00---1.409.6653.05---34.30--
Fuse Medical Inc18.40m3.63m2.88m31.001.08--0.78130.15660.0360.0360.2307-0.00310.95930.70185.75593,671.9018.910.750448.451.3564.9554.9819.720.65520.3143-1.131.12---8.67-6.72295.1134.66----
Axim Biotechnologies Inc92.90k-4.14m3.49m6.00------37.54-0.0163-0.01630.0003-0.03240.0233----15,483.33-103.73-154.34---390.7316.94---4,451.97-36,362.71---3.14----345.05-27.38-29.10------
Data as of Mar 03 2026. Currency figures normalised to Aethlon Medical Inc's reporting currency: US Dollar USD

Institutional shareholders

1.69%Per cent of shares held by top holders
HolderShares% Held
Ikarian Capital LLCas of 31 Dec 202514.36k1.48%
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 20252.05k0.21%
Citigroup Global Markets, Inc. (Investment Management)as of 31 Dec 202533.000.00%
Group One Trading LLCas of 31 Dec 202514.000.00%
BlackRock Fund Advisorsas of 31 Dec 202510.000.00%
Bank of America, NA (Private Banking)as of 31 Dec 20256.000.00%
Wells Fargo Clearing Services LLCas of 31 Dec 20253.000.00%
Danske Bank A/S (Investment Management)as of 31 Dec 20251.000.00%
Geode Capital Management LLCas of 31 Dec 20250.000.00%
Two Sigma Investments LPas of 31 Dec 20250.000.00%
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.